LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Disc Medicine today and set a price target of $100.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rami Katkhuda has given his Buy rating due to a combination of factors, including Disc Medicine’s strong balance sheet and extended cash runway that is expected to fund operations into 2029. He views this financial position as providing sufficient flexibility to advance multiple clinical programs while absorbing regulatory delays without the need for near‑term dilutive financing.
Katkhuda also believes there is meaningful value in the pipeline, particularly in bitopertin, where he sees a viable route to full approval despite the recent Complete Response Letter. His confidence is supported by prior clinical data showing robust PPIX reductions and associated gains in light tolerance, as well as the upcoming APOLLO Phase III readout in Q4 2026, which he views as a key catalyst that could unlock substantial upside if positive.